文献速递精神分裂症与精神病性障碍儿童青少年精神

针对精神病超高危年轻人的序贯适应性干预策略:STEP序贯多阶段随机试验

A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

STEP序贯多阶段随机试验在澳大利亚Orygen临床项目中招募342名12至25岁精神病超高危个体,评估序贯适应性干预策略的效果。结果显示各阶段缓解率分别为8.5%、10.3%和11.4%,任何阶段累计27.2%达到缓解;12个月精神病转化率为13.5%,全程样本转化率中等,缓解率低于预期。

要点

  • 序贯适应性干预各阶段缓解率低(8.5%-11.4%),累计仅27.2%达到缓解。
  • 12个月精神病转化率全程13.5%,未缓解者达17.4%,已缓解者仅3.3%。
  • SPS与CBCM、CBCM联合氟西汀与安慰剂之间功能、症状及转化率无显著差异。

核心结论

  • 在精神病超高危年轻人中,序贯适应性干预策略的精神病转化率中等,缓解率低于预期。
  • 所有组别均显示轻度至中度功能与症状改善,但通常未达到缓解标准。
  • 研究结果证实该人群存在显著且持续的疾病负担,对现有治疗反应性相对较差。

研究设计与样本

  • STEP为序贯多阶段随机试验(SMART),在澳大利亚墨尔本Orygen临床项目中开展。
  • 招募12至25岁符合CAARMS精神病超高危标准且寻求治疗的个体,2016年4月至2019年1月共筛查1343人,纳入342人。
  • 干预分三步:第1步6周支持与问题解决(SPS);第2步20周认知行为个案管理(CBCM)对比SPS;第3步26周CBCM联合氟西汀对比CBCM联合安慰剂,并嵌入ω-3脂肪酸或低剂量抗精神病药的快速失败选项。
  • 未缓解者逐级推进,缓解者接受SPS或监测最长12个月。

主要发现

  • 样本共342人(198名女性;平均[SD]年龄17.7[3.1]岁)。
  • 第1、2、3步的缓解率分别为8.5%、10.3%、11.4%,任何阶段累计27.2%达到缓解标准。
  • 缓解者中SPS与监测的复发率无显著差异(第1步:65.1% vs 58.3%;第2步:37.7% vs 47.5%)。
  • SPS与CBCM之间、CBCM联合氟西汀与CBCM联合安慰剂之间在功能、症状及转化率上均无显著差异。
  • 12个月精神病转化率:全样本13.5%,曾缓解者3.3%,未缓解者17.4%。

关键数值与推荐

  • 缓解定义反映持续的症状与功能改善,各步缓解率分别为8.5%、10.3%、11.4%。
  • 12个月转化率全样本13.5%,曾缓解者3.3%,未缓解者17.4%。
  • 复发率比较:第1步SPS 65.1% vs 监测58.3%;第2步SPS 37.7% vs 监测47.5%,均无显著差异。

临床怎么用

  • 对精神病超高危年轻人可采用序贯适应性干预框架,但需预期缓解率较低。
  • SPS、CBCM及CBCM联合氟西汀在该人群中未显示显著疗效差异,临床选择需权衡个体情况。
  • 缓解后SPS与监测的复发风险相近,提示需持续关注复发并个体化随访。
  • 未缓解者转化风险较高(17.4%),应加强监测与干预强度。

局限性

  • 缓解率低于预期部分反映所设缓解标准较为严格。
  • 真实世界治疗保真度和依从性存在挑战。
  • 研究在单一临床项目开展,外推需谨慎。
  • 需要进一步适应性试验以解决上述挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis. OBJECTIVE: To determine the effectiveness of a sequential and adaptive intervention strategy for individuals at ultrahigh risk of psychosis. DESIGN, SETTING, AND PARTICIPANTS: The Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia. Individuals aged 12 to 25 years who were seeking treatment and met criteria for ultrahigh risk of psychosis according to the Comprehensive Assessment of At-Risk Mental States were recruited between April 2016 and January 2019. Of 1343 individuals considered, 342 were recruited. INTERVENTIONS: Step 1: 6 weeks of support and problem solving (SPS); step 2: 20 weeks of cognitive-behavioral case management (CBCM) vs SPS; and step 3: 26 weeks of CBCM with fluoxetine vs CBCM with placebo with an embedded fast-fail option of ω-3 fatty acids or low-dose antipsychotic medication. Individuals who did not remit progressed through these steps; those who remitted received SPS or monitoring for up to 12 months. MAIN OUTCOMES AND MEASURES: Global Functioning: Social and Role scales (primary outcome), Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Montgomery-Åsberg Depression Rating Scale, quality of life, transition to psychosis, and remission and relapse rates. RESULTS: The sample comprised 342 participants (198 female; mean [SD] age, 17.7 [3.1] years). Remission rates, reflecting sustained symptomatic and functional improvement, were 8.5%, 10.3%, and 11.4% at steps 1, 2, and 3, respectively. A total of 27.2% met remission criteria at any step. Relapse rates among those who remitted did not significantly differ between SPS and monitoring (step 1: 65.1% vs 58.3%; step 2: 37.7% vs 47.5%). There was no significant difference in functioning, symptoms, and transition rates between SPS and CBCM and between CBCM with fluoxetine and CBCM with placebo. Twelve-month transition rates to psychosis were 13.5% (entire sample), 3.3% (those who ever remitted), and 17.4% (those with no remission). CONCLUSIONS AND RELEVANCE: In this sequential multiple assignment randomized trial, transition rates to psychosis were moderate, and remission rates were lower than expected, partly reflecting the ambitious criteria set and challenges with real-world treatment fidelity and adherence. While all groups showed mild to moderate functional and symptomatic improvement, this was typically short of remission. While further adaptive trials that address these challenges are needed, findings confirm substantial and sustained morbidity and reveal relatively poor responsiveness to existing treatments. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02751632.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. McGorry PD, Mei C, Amminger GP, et al. A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial. JAMA Psychiatry. 2023. PMID: 37378974. doi:10.1001/jamapsychiatry.2023.1947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。